We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-8.13%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$611M
AUM Growth
-$116M
Cap. Flow
+$26.6M
Cap. Flow %
4.34%
Top 10 Hldgs %
81.82%
Holding
34
New
8
Increased
16
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$25.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$18.8M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$16.4M
4
DVAX
Dynavax Technologies
DVAX
+$7.03M
5
COGT icon
Cogent Biosciences
COGT
+$7.03M

Top Sells

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$7.02M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.53M
4
VERA icon
Vera Therapeutics
VERA
+$754K
5
VRDN icon
Viridian Therapeutics
VRDN
+$187K

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$133M 21.74%
3,003,668
+103,668
+4% +$5.29M
CLDX icon
2
Celldex Therapeutics
CLDX
$2.77B
$88.1M 14.4%
3,200,000
+600,000
+23% +$18.8M
PCVX icon
3
Vaxcyte
PCVX
$7.89B
$66.4M 10.86%
1,302,407
+2,407
+0.2% +$119K
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$52.3M 8.55%
3,600,000
+337,996
+10% +$6.39M
VERA icon
5
Vera Therapeutics
VERA
$2.54B
$40.5M 6.63%
2,956,053
-43,947
-1% -$754K
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.75B
$30.3M 4.96%
1,818,657
+843,359
+86% +$16.4M
TSVT
7
DELISTED
2seventy bio
TSVT
$23.3M 3.82%
5,953,825
+1,063,119
+22% +$6.97M
WVE icon
8
Wave Life Sciences
WVE
$1.12B
$22.6M 3.7%
3,932,082
+7,480
+0.2% +$34.1K
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.37B
$22.2M 3.63%
3,133,193
+284,996
+10% +$2.05M
COGT icon
10
Cogent Biosciences
COGT
$6.79B
$21.5M 3.52%
2,210,125
+592,734
+37% +$7.03M
LQDA icon
11
Liquidia Corp
LQDA
$7.67B
$12.7M 2.07%
2,000,000
+357,756
+22% +$2.58M
SLRN
12
DELISTED
ACELYRIN
SLRN
$12.2M 2%
+1,200,000
New +$25.5M
AMRN
13
Amarin Corp
AMRN
$284M
$11.1M 1.81%
601,148
+1,148
+0.2% +$24.9K
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$10.7M 1.76%
699,681
-9,817
-1% -$187K
TSHA icon
15
Taysha Gene Therapies
TSHA
$1.59B
$10.4M 1.7%
+3,281,313
New +$6.13M
TVTX icon
16
Travere Therapeutics
TVTX
$5.33B
$8.56M 1.4%
957,502
-497,228
-34% -$7.02M
BNR
17
Burning Rock Biotech
BNR
$94.4M
$8.24M 1.35%
850,000
– –
DVAX
18
DELISTED
Dynavax Technologies
DVAX
$7.38M 1.21%
+500,000
New +$7.03M
SNDX icon
19
CALL
Syndax Pharmaceuticals
SNDX
$1.84B
$5.81M 0.95%
+400,000
New +$7.57M
STRO icon
20
Sutro Biopharma
STRO
$379M
$5.39M 0.88%
155,268
+5,268
+4% +$230K
CRBU icon
21
Caribou Biosciences
CRBU
$156M
$5.11M 0.84%
+1,068,527
New +$6.63M
CNTA
22
DELISTED
Centessa Pharmaceuticals
CNTA
$4.73M 0.77%
730,472
+1,395
+0.2% +$9.54K
IMVT icon
23
PUT
Immunovant
IMVT
$8.09B
$3.84M 0.63%
+100,000
New +$2.26M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.02B
$2.9M 0.48%
235,176
-1,069,156
-82% -$10.9M
PBYI icon
25
Puma Biotechnology
PBYI
$406M
$1.25M 0.2%
473,975
+905
+0.2% +$3.08K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Kynam Capital Management held 34 positions worth $611M, down 16% from $727M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management deployed $26.6M of net new capital in Q3 2023, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was ACELYRIN: 1,200,000 shares worth $12.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Olema Pharmaceuticals, an estimated $10.9M trimmed.

  • Kynam Capital Management's largest Q3 2023 buy was ACELYRIN: 1,200,000 shares worth $12.2M.
  • Kynam Capital Management added most to Celldex Therapeutics in Q3 2023, an estimated $18.8M increase.
  • Kynam Capital Management's biggest Q3 2023 reduction was Olema Pharmaceuticals, cutting an estimated $10.9M.
  • Kynam Capital Management fully exited Rhythm Pharmaceuticals in Q3 2023, selling an estimated $1.53M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $611M portfolio in Q3 2023.
  • Kynam Capital Management opened 8 new positions and closed 4 in Q3 2023.
  • Kynam Capital Management's portfolio value fell 16% quarter-over-quarter to $611M.

Based on Kynam Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.